查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997376

肺癌手術市場：2026-2032年全球市場預測（依治療方法、產品類型、癌症類型和最終用戶分類）

Lung Cancer Surgery Market by Approach, Product Type, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺癌手術市場價值將達到 69.4 億美元，到 2026 年將成長至 76 億美元，到 2032 年將達到 142.5 億美元，複合年成長率為 10.82%。

主要市場統計數據
基準年 2025 69.4億美元
預計年份：2026年 76億美元
預測年份 2032 142.5億美元
複合年成長率 (%) 10.82%

全面而實用的介紹，涵蓋臨床創新、不斷發展的護理模式以及影響現代肺癌外科手術實踐的商業性因素。

肺癌手術正處於一個轉折點，臨床創新、不斷發展的護理模式以及不斷變化的報銷和貿易政策相互交織，重塑臨床醫生和醫療保健系統提供根治性和姑息性干預的方式。影像學、手術全期護理和手術平台的進步正穩步推動複雜切除術從高併發症的開胸手術轉向低併發症的手術方式。同時，產業重組和技術合作正在加速精密儀器在常規手術室中的應用。此外，全球供應鏈和關稅體系的變化也正在改變醫院系統和門診手術中心的籌資策略、資本規劃和供應商選擇流程。

臨床技術的進步、平台整合以及分散式醫療服務的普及，如何重新定義肺癌手術的外科實務和商業策略？

過去十年，肺癌手術領域發生了翻天覆地的變化，這主要得益於三個相互關聯的因素：臨床技術的進步、平台主導的整合以及醫療服務分散化。影像技術的改進、圍手術全期通訊協定的最佳化以及外科培訓計畫的加強，使得微創手術從小眾選擇轉變為許多可切除腫瘤的主流治療方案。機器人輔助胸腔鏡手術平台和先進的胸腔鏡技術，即使在解剖結構受限的區域也能實現更精準的切除，縮短了患者的康復時間，並擴大了老年患者和併發症多種疾病患者的手術適應症。

了解關稅變化將如何重塑整個肺癌手術生態系統中的製造地、採購韌性和商業性重點。

宣布2025年實施的關稅調整的累積影響將遠不止於表面上的採購成本，還將波及供應鏈、產品生命週期規劃以及整體醫療設備籌資策略。關稅調整將影響有關國內庫存水準、區域製造地和供應商選擇的決策，促使醫療服務提供者和製造商重新評估總交付成本和採購韌性。對於高度專業化的醫療設備和耗材，尤其是那些集中在少數全球供應商手中的產品，關稅帶來的成本壓力可能會加速有關捆綁定價、長期服務合約和本地庫存協議的談判。

從詳細的細分觀點出發，將手術方法、醫療設備分類、腫瘤組織學類型和臨床環境與採購和臨床實施趨勢連結起來。

基於細分市場的洞察揭示了不同手術方式、產品類型、癌症組織學亞型和醫療機構中，在產品採納和採購方面存在的細微差異。這些差異都會影響臨床決策和商業性定位。就手術方式而言，微創手術和開放性手術之間的差異尤其顯著。微創手術路徑分為機器人輔助胸腔鏡和視訊輔助胸腔鏡，其中機器人系統通常被定位為高階平台，結合了先進的可視化功能和器械移動性。機器人輔助胸腔鏡的代表是成熟的機器人平台，這些平台整合了人體工學和手術分析功能。另一方面，視訊輔助胸腔鏡又分為多孔和單孔兩種方式，分別著重於不同的器械特性和切口策略。這些差異會影響訓練需求、手術室配置和輔助設備需求。

美洲、歐洲、中東、非洲和亞太地區的區域差異如何影響採用率、監管策略和採購選擇？

區域趨勢影響肺癌外科領域的應用模式、監管重點和投資意圖。在美洲，對技術驅動型醫療的高度重視以及高度專業化醫療中心的集中，推動了對整合平台和高階耗材的需求。同時，健保報銷機制和醫院整合正在影響採購時機和採購流程的複雜程度。該地區的臨床網路和卓越中心模式正在加速手術創新技術的推廣，同時也給供應商帶來了競爭壓力，要求其在治療效果和降低醫療總成本方面展現出明顯的價值。

策略性的企業策略和差異化的供應商模式，結合平台擴展、證據產生和供應彈性，以增強競爭優勢。

主要企業正透過平台擴張、策略夥伴關係以及對先進視覺化、儀器移動性和分析等基礎技術的定向投資來鞏固自身地位。成熟的平台供應商持續投資於模組化和服務模式，以確保耗材收入，而新興競爭對手則專注於利基創新，以解決特定的手術難題和成本效益差距。透過經銷夥伴、共同開發契約和臨床研究合作等方式進行公司間合作，仍是加速臨床療效檢驗和市場准入的常見途徑。

為領導者提供切實可行的優先建議，以協調臨床證據、供應彈性、培訓基礎設施和適應性商業模式，從而實現永續推廣。

產業領導者必須採取多管齊下的方法，將臨床價值、供應鏈韌性和商業性靈活性結合在一起。首先，投資可驗證的臨床證據和上市後監測，將設備性能與有意義的患者療效和營運指標連結起來。透過將技術部署與可衡量的結果（例如減少併發症、縮短住院時間和手術時間）掛鉤，相關人員可以強化基於價值的採購概念，並加快在醫院和門診環境中的部署。其次，探索區域組裝和本地夥伴關係，以實現採購多元化、降低關稅風險並減少前置作業時間波動。這種方法可確保服務的連續性，並穩定大批量專案中的耗材供應。

我們嚴謹透明的檢驗框架，結合了與臨床醫生的直接互動、對二手證據的審查以及反覆的三角驗證，產生了可操作且令人信服的研究結果。

本調查方法結合了系統性的原始資料收集和嚴格的第二手資料審查及檢驗，以確保資料的可靠性和有效性。原始資料收集包括對不同地區和醫療機構的胸腔外科醫師、手術室主管、採購經理和醫療設備公司高階主管進行結構化訪談，並輔以現場考察，以了解工作流程的限制因素和器械使用情況。這些研究重點關注手術決定因素、訓練需求、採購標準以及最終使用者對醫療設備在實際臨床環境中表現的感知。

為指導肺癌手術的策略決策，總結出整合臨床創新、營運要求和商業性考慮的簡潔結論。

肺癌手術的演進是技術成熟、實證實踐應用以及醫療服務模式轉型三者共同作用的結果，這為製造商、醫療服務提供者和政策制定者帶來了巨大的機會和複雜的挑戰。微創手術的興起、醫療設備生態系統的平台化以及部分手術在門診的開展，都要求培訓、採購和產品開發等各個環節進行協調應對。同時，貿易政策的變化和關稅調整也要求企業更加重視供應鏈設計和商業性適應能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依手術方法分類的肺癌手術市場

  • 微創
    • 機器人輔助胸腔鏡手術（RATS）
    • 視訊輔助胸腔鏡手術（VATS）
      • 多孔型
      • 單孔型
  • 開胸手術

第9章：肺癌手術市場：依產品類型分類

  • 入路裝置及套管針
  • 內視鏡和視覺化系統
  • 能源設備
    • 先進的雙極裝置
    • 電外科設備
    • 超音波能量裝置
  • 訂書機
    • 手動訂書機
    • 電動訂書機

第10章：以癌症類型分類的肺癌手術市場

  • 非小細胞肺癌
    • 腺癌
    • 大細胞癌
    • 鱗狀細胞癌
  • 小細胞肺癌

第11章 肺癌手術市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章 肺癌手術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺癌手術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺癌手術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肺癌手術市場

第16章：中國肺癌手術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ambu A/S
  • B. Braun SE
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Intuitive Surgical, Inc.
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Medtronic plc
  • Olympus Corporation
  • Siemens Healthineers AG
  • Smith & Nephew plc
  • Stryker Corporation
  • Teleflex Incorporated
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-501246436957

The Lung Cancer Surgery Market was valued at USD 6.94 billion in 2025 and is projected to grow to USD 7.60 billion in 2026, with a CAGR of 10.82%, reaching USD 14.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.94 billion
Estimated Year [2026] USD 7.60 billion
Forecast Year [2032] USD 14.25 billion
CAGR (%) 10.82%

An integrated and actionable introduction that maps clinical innovation, care model evolution, and commercial forces shaping contemporary lung cancer surgical practice

Lung cancer surgery sits at an inflection point where clinical innovation, shifting care models, and evolving reimbursement and trade policy intersect to reshape how clinicians and health systems deliver curative and palliative interventions. Advances in imaging, perioperative care, and surgical platforms have steadily moved complex resections away from high-morbidity open thoracotomy toward lower-morbidity approaches, while industry consolidation and technology partnerships have accelerated the translation of precision tooling into everyday operating rooms. At the same time, changes in global supply chains and tariff regimes are altering procurement strategy, capital planning, and vendor selection processes for hospital systems and ambulatory surgical centers.

This executive summary synthesizes clinical trends, technology adoption dynamics, supply chain sensitivities, and stakeholder imperatives to give leaders a clear line of sight into where clinical practice and commercial opportunity converge. The analysis is grounded in structured primary research with surgeons, hospital leaders, device manufacturers, and payers, supplemented by rigorous secondary review of device approvals, clinical trial endpoints, and regulatory guidance. The goal is to provide practical insight that supports tactical decisions-equipment procurement, training investments, alliance formation-and strategic planning for product development and market entry.

Readers will find an integrated view that connects device-level considerations with procedural pathways and end-user needs, highlighting the interplay between robotic and thoracoscopic modalities, the role of advanced energy and stapling technologies, and the operational requirements of different care settings. The summary prioritizes clarity and actionable intelligence so that multidisciplinary teams can align clinical goals with commercial realities.

How clinical technique evolution, platform integration, and decentralized care delivery collectively redefine procedural practice and commercial strategies in lung cancer surgery

Over the last decade, the landscape of lung cancer surgery has undergone transformative shifts driven by three interlinked vectors: clinical technique evolution, platform-driven integration, and care delivery decentralization. Minimally invasive approaches have moved from niche alternatives to mainstream options for many resectable tumors, supported by improved imaging, perioperative pathways, and surgeon training programs. Robotic assisted thoracic platforms and refined thoracoscopic techniques have enabled more precise dissection in anatomically constrained fields, reducing recovery time and widening candidacy for surgery among older and comorbid patients.

At the same time, device ecosystems have become platform-centered, whereby visualization, energy, and stapling technologies are designed to function seamlessly within a system architecture. This integration reduces procedural friction and shortens learning curves, yet it also intensifies competitive differentiation around ecosystem lock-in and bundled procurement models. Suppliers increasingly invest in software-enabled capabilities-enhanced visualization, image-guided navigation, and procedural analytics-that extend value beyond hardware and create recurring revenue pathways tied to consumables and service agreements.

Care delivery has shifted toward a more distributed model, with ambulatory surgical centers participating in less complex thoracic resections and hospitals concentrating high-acuity cases. This decentralization requires adaptable instruments and streamlined supply chains that support site-of-care diversification. Concurrently, training and credentialing programs have expanded to accommodate the technical demands of advanced minimally invasive techniques, emphasizing simulation, proctorship, and competency-based assessment. Collectively, these shifts are redefining clinical workflows, supplier negotiations, and investment priorities for providers and manufacturers alike.

Understanding how tariff changes reshape manufacturing footprints, procurement resilience, and commercial priorities across the lung cancer surgical ecosystem

The cumulative impact of tariff changes announced for implementation in 2025 extends beyond headline procurement costs and reverberates across supply chains, product lifecycle planning, and device sourcing strategies. Tariff adjustments influence decisions around domestic inventory levels, regional manufacturing footprints, and supplier selection, prompting health systems and manufacturers to reassess total landed cost and procurement resilience. For devices and consumables that are highly specialized and concentrated among a limited set of global suppliers, tariff-induced cost pressure can accelerate negotiations on bundled pricing, long-term service contracts, and local stocking agreements.

Manufacturers respond to tariff environments by reshaping supply chain architecture-either by shifting production to lower-tariff jurisdictions, establishing local assembly operations, or redesigning components to meet local content thresholds. These responses have downstream effects on product availability timelines, replacement part logistics, and the predictability of capital equipment lead times. For providers, the result is a renewed focus on procurement agility, including multi-supplier sourcing strategies and contractual terms that protect against volatility in cross-border trade.

Tariff-driven cost pressures also influence commercial prioritization, where companies may choose to concentrate market development efforts in regions with stable trade terms while adapting pricing and service models in others. Clinically, some hospitals may defer non-urgent capital acquisitions or prioritize modular investments that are less exposed to cross-border tariff fluctuations. In aggregate, the tariff landscape reshapes both near-term purchasing behavior and long-term strategic investment choices across the lung cancer surgery ecosystem.

Deep segmentation-driven perspectives that link surgical approaches, device classes, tumor histologies, and care settings to procurement and clinical adoption dynamics

Segmentation insights reveal nuanced drivers of adoption and procurement across approaches, product types, cancer histologies, and care settings, each of which influences clinical decision-making and commercial positioning. Within the approach dimension, the contrast between minimally invasive and open surgery is pronounced: minimally invasive pathways split into robotic assisted thoracic surgery and video assisted thoracoscopic surgery, with robotic systems frequently positioned as premium platforms that bundle advanced visualization and instrument articulation. Robotic assisted thoracic surgery is represented by established robotic platforms that offer integrated ergonomics and procedural analytics, while video assisted thoracoscopic surgery differentiates into multiportal and uniportal techniques that prioritize different instrument profiles and incision strategies. These distinctions affect training needs, OR setup, and accessory demand.

Product typology further refines the competitive landscape, with access devices and trocars, endoscopes and visualization systems, energy devices, and stapling devices each playing distinct roles in procedural efficiency and safety. Energy modalities divide into advanced bipolar, electrosurgical, and ultrasonic technologies, each with trade-offs in hemostasis, tissue effect, and instrument ergonomics. Stapling solutions vary between manual and powered staplers, where powered stapling can reduce surgeon effort in difficult angles and potentially improve consistency in staple formation. These product-level differences shape procurement conversations, capital budgeting, and consumable contracts.

Cancer type segmentation also guides procedural selection and device requirements. Non-small cell lung cancer encompasses adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, each with differing typical tumor locations and resection margins that influence the choice of approach and instrumentation. Small cell lung cancer, with its distinct biology and treatment paradigms, often prompts integrated oncologic planning where surgery is coordinated with systemic therapy. Finally, end-user segmentation-spanning ambulatory surgical centers and hospitals-dictates operational constraints, with ambulatory centers emphasizing streamlined instrument sets and rapid turnover while hospitals manage a broader case mix and complex perioperative care. Together, these segmentation layers inform go-to-market strategies, training investments, and product roadmaps for stakeholders across the ecosystem.

How regional heterogeneity across the Americas, Europe, Middle East and Africa, and Asia-Pacific drives differentiated adoption, regulatory strategy, and procurement choices

Regional dynamics shape adoption patterns, regulatory priorities, and investment appetite across the lung cancer surgery landscape. In the Americas, a strong emphasis on technology-enabled care and a high concentration of advanced specialty centers drive demand for integrated platforms and premium consumables, while reimbursement mechanisms and hospital consolidation influence purchasing windows and procurement sophistication. Clinical networks and center-of-excellence models here facilitate rapid dissemination of procedural innovations, yet they also create competitive pressure for suppliers to demonstrate clear value in outcomes and total cost of care.

In Europe, Middle East & Africa, variability across national health systems and regulatory pathways leads to heterogeneous adoption timelines. Western European markets tend to adopt new surgical technologies through structured health technology assessment and centralized procurement, whereas other parts of this region may prioritize cost-effective solutions and local manufacturing partnerships. Regulatory harmonization efforts and cross-border clinical collaborations often accelerate evidence generation, but differing reimbursement frameworks require adaptive commercial approaches.

Asia-Pacific presents a dynamic mix of high-volume clinical demand and rapidly evolving surgical capacity. Diverse market maturity across countries drives differentiated strategies: some markets prioritize rapid uptake of robotic and thoracoscopic systems supported by expanding surgical training programs, while others emphasize scalable, lower-cost solutions to broaden access. Across all regions, supply chain resilience, tariff exposure, and local clinical evidence shape investment decisions and the prioritization of product features that align with regional procedural volumes and provider capabilities.

Strategic corporate maneuvers and differentiated supplier models that combine platform expansion, evidence generation, and supply resilience to drive competitive advantage

Leading companies are consolidating their positions through platform expansion, strategic partnerships, and targeted investments in enabling technologies such as advanced visualization, instrument articulation, and analytics. Established platform providers continue to invest in modularity and service models that lock in consumable revenue, while emerging competitors focus on niche innovations that address specific procedural pain points or cost-efficiency gaps. Cross-company collaboration-through distribution partnerships, co-development agreements, and clinical research alliances-remains a common pathway to accelerate clinical validation and market entry.

Supplier strategies increasingly emphasize lifecycle services, including training programs, proctorship, and remote monitoring capabilities that reduce adoption friction and demonstrate procedural consistency. Companies that invest in evidence generation-clinical outcomes, comparative effectiveness studies, and real-world data collection-gain an advantage in procurement conversations where institutions seek to align technology spend with measurable quality improvements. At the same time, manufacturing and supply chain optimization, including localization of assembly and broadened supplier bases for critical components, have become central to maintaining product availability amid trade and logistical uncertainty.

Competitive dynamics also reflect varied go-to-market models. Some firms prioritize direct engagement with large health systems and integrated delivery networks, offering bundled solutions and long-term service agreements, while others target ambulatory surgical centers and smaller hospitals through distributor-led channels and cost-optimized device offerings. Successful companies balance clinical credibility with operational flexibility, aligning product roadmaps to both high-acuity centers and resource-constrained settings.

Practical and prioritized recommendations for leaders to align clinical evidence, supply resilience, training infrastructure, and adaptive commercial models for sustained adoption

Industry leaders must adopt a multi-pronged approach that aligns clinical value with supply chain resilience and commercial agility. First, invest in demonstrable clinical evidence and post-market surveillance that tie device performance to meaningful patient outcomes and operational metrics. By linking technology adoption to measurable reductions in complications, length of stay, and OR time, stakeholders can strengthen value-based procurement arguments and accelerate uptake across both hospitals and ambulatory settings. Second, diversify sourcing and consider regional assembly or localized partnerships to mitigate tariff exposure and reduce lead-time variability. This approach protects service continuity and stabilizes consumable supply for high-volume programs.

Third, prioritize training and competency frameworks that shorten the adoption curve for minimally invasive techniques, leveraging simulation, proctorship, and competency-based credentialing. Robust training programs not only increase procedural safety but also reduce institutional resistance to capital investments. Fourth, design flexible commercial models that reflect site-of-care differences; offer modular capital options, subscription-based consumable agreements, and bundled service packages that align with the budgets and operational rhythms of diverse end-users. Finally, foster collaborative relationships with clinicians and payers to co-develop pathways that integrate surgical interventions with broader oncology care plans, ensuring that device innovations translate into holistic improvements in patient management.

A rigorous and transparent research framework combining primary clinician engagement, secondary evidence review, and iterative triangulation to produce actionable and defensible insights

The research methodology blends systematic primary data collection with rigorous secondary review and triangulation to ensure reliability and relevance. Primary research comprised structured interviews with thoracic surgeons, OR directors, procurement leaders, and device executives across diverse geographies and care settings, supplemented by observational site visits to understand workflow constraints and instrument utilization. These engagements focused on procedural decision drivers, training needs, procurement criteria, and real-world device performance as perceived by end-users.

Secondary review incorporated regulatory filings, clinical trial registries, technology guidance documents, and peer-reviewed literature to contextualize primary findings within the broader evidence base. Data triangulation involved cross-checking interview insights against documented clinical outcomes and device registries to identify consistent patterns and reconcile divergent perspectives. Segmentation was applied deliberately to map findings across surgical approach, product type, cancer histology, and end-user categories, enabling granular recommendations tailored to specific clinical and commercial scenarios.

Quality assurance processes included methodological audits, validation interviews with neutral clinical advisors, and iterative refinement of conclusions based on emerging evidence. The result is a robust synthesis that balances practitioner experience with documented clinical and regulatory signals, producing insights that are both actionable and defensible for decision-makers.

A concise conclusion synthesizing clinical innovation, operational imperatives, and commercial considerations to guide strategic decision-making in lung cancer surgery

The trajectory of lung cancer surgery reflects a convergence of technological maturation, evidence-driven adoption, and shifting care delivery models that together create significant opportunities and complex challenges for manufacturers, providers, and policy-makers. The move toward minimally invasive approaches, the platformization of device ecosystems, and the decentralization of certain procedural volumes to ambulatory settings demand coordinated responses across training, procurement, and product development. Simultaneously, trade policy shifts and tariff adjustments require heightened attention to supply chain design and commercial adaptability.

Leaders who integrate clinical evidence with operational planning, diversify their supply strategies, and invest in scalable training infrastructures will be best positioned to capture clinical and commercial value. Strategic partnerships, targeted evidence generation, and flexible commercial models will differentiate organizations in a landscape where procedural capability and system compatibility increasingly determine adoption. By aligning technological innovation with the practical realities of hospital and ambulatory operations, stakeholders can improve patient outcomes while sustaining business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Surgery Market, by Approach

  • 8.1. Minimally Invasive
    • 8.1.1. Robotic Assisted Thoracic Surgery (Rats)
    • 8.1.2. Video Assisted Thoracoscopic Surgery (Vats)
      • 8.1.2.1. Multiportal
      • 8.1.2.2. Uniportal
  • 8.2. Open Surgery

9. Lung Cancer Surgery Market, by Product Type

  • 9.1. Access Devices And Trocars
  • 9.2. Endoscopes And Visualization Systems
  • 9.3. Energy Devices
    • 9.3.1. Advanced Bipolar Devices
    • 9.3.2. Electrosurgical Devices
    • 9.3.3. Ultrasonic Energy Devices
  • 9.4. Stapling Devices
    • 9.4.1. Manual Staplers
    • 9.4.2. Powered Staplers

10. Lung Cancer Surgery Market, by Cancer Type

  • 10.1. Non Small Cell Lung Cancer
    • 10.1.1. Adenocarcinoma
    • 10.1.2. Large Cell Carcinoma
    • 10.1.3. Squamous Cell Carcinoma
  • 10.2. Small Cell Lung Cancer

11. Lung Cancer Surgery Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Lung Cancer Surgery Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lung Cancer Surgery Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lung Cancer Surgery Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Lung Cancer Surgery Market

16. China Lung Cancer Surgery Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ambu A/S
  • 17.6. B. Braun SE
  • 17.7. Becton Dickinson and Company
  • 17.8. Boston Scientific Corporation
  • 17.9. Fujifilm Holdings Corporation
  • 17.10. GE HealthCare Technologies Inc.
  • 17.11. Intuitive Surgical, Inc.
  • 17.12. Johnson & Johnson
  • 17.13. KARL STORZ SE & Co. KG
  • 17.14. Medtronic plc
  • 17.15. Olympus Corporation
  • 17.16. Siemens Healthineers AG
  • 17.17. Smith & Nephew plc
  • 17.18. Stryker Corporation
  • 17.19. Teleflex Incorporated
  • 17.20. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER SURGERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUNG CANCER SURGERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 173. GCC LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 201. G7 LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 203. G7 LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 211. NATO LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 213. NATO LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. NATO LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)